Last updated 5 days ago
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
490 patients around the world
Available in Argentina, Mexico, United States, Colombia, Brazil, Peru
Bristol-Myers Squibb
47Research sites
490Patients around the world
This study is for people with
Lupus
Systemic lupus erythematosus
Requirements for the patient
To 75 Years
All Gender
Medical requirements
Sites
Instituto de Investigaciones Clínicas Tucumán
Recruiting
Instituto de Investigaciones Clínicas Quilmes
Recruiting
Hospital Córdoba
Recruiting
Aprillus Asistencia e Investigación
Recruiting
Instituto de Reumatología - Ir Medical Center S.A. - Mendoza
Recruiting
Fundación CIDEA - Buenos Aires
Recruiting
Private Practice - Dr. Mariana Natalia Rivera
Recruiting
Hospital General de Agudos J. M. Ramos Mejía - Buenos Aires, CABA
Recruiting
Hospital do Rim - HRIM– Fundação Oswaldo Ramos
Recruiting
Santa Casa de Misericórdia de Belo Horizonte
Recruiting
StudyPOETYK SLE-1
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Systemic lupus erythematosus
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05617677
